Title for MeetingAbstracts
Alphabetical listing of titles
Z-100 a Mycobacterium Tuberculosis-derived arabinomannan, induces MIP-1a and inhibits the replication of M-tropic HIV in macrophage cultures.
Z-isomers of the adenine and guanine analogs are highly active against ganciclovir-resistant human cytomegalovirus (HCMV) UL97 mutants.
Zairean HIV(+) patiients ability to afford health care.
Zairian HIV-1 variable and hypervariable envelope fragments.
Zalcitabine (ddC) exposure: lack of impact on CD4 and weight response during combination therapy with zidovudine (ZDV) after previous ZDV therapy.
Zalcitabine (ddC) in combination with zidovudine (ZDV) for treatment of advanced HIV disease. A multicenter, open- label, non comparative study.
Zalcitabine (ddC) in combination with zidovudine (ZDV,AZT) for treatment of advanced HIV disease. A multicenter, open label, non comparative study.
Zalcitabine (ddC) in zidovudine (ZDV) intolerant individuals: European Expanded Access Programme.
Zambia AIDS awareness and condom consumer usage survey.
Zambian National STD Control Program: a model program.
Zambian National STD Control Program: the model program in Africa.
Zanamivir and Rimantadine Susceptibility of Virus Isolates from a Clinical Trial Comparing the Use of Zanamivir or Rimantadine in the Control of Nursing Home Influenza Outbreaks.
ZDV and ddI resistance in HIV isolated from patients enrolled in the alpha ddI trial.
ZDV resistance (ZDVR) mutations in ZDV exposed mother infant pairs: preliminary findings from the women and infants transmission study (WITS).
ZDV resistance mutations increase HIV-1 replication in 4 drug-free PBMC stimulated after infection.
ZDV-use, HIV-testing and reproductive behavioral responses related to knowledge of ZDV to reduce infant HIV transmission.
Zero work hour procedures for complex new technology drugs and biologicals.
Ziagen (abacavir, ABC, 1592) combined with 3TC & ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naive subjects (CNAA3003).
Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy (ART) naive adults at 24 weeks (CNA3005).
Zidovudine & alpha-interferon vs zidovudine alone in HIV infected persons with CD4+ cell counts of 150-500/mm3--results of the 'ZIDON' trial.
Zidovudine (AZT) and interferon-alpha (IFN) susceptibilities correlate with treatment duration and response.
Zidovudine (AZT) and Pneumocystis prophylaxis (PCP Px) defers AIDS until immunodeficiency is more severe.
Zidovudine (AZT) effect on morphine and codeine immunotoxicity.
Zidovudine (AZT) has an early beneficial effect on CD4+/CD29+ "memory" T cells in HIV infected persons.
Zidovudine (AZT) in HIV positive haemophiliacs.
Zidovudine (AZT) Increases Endothelial Superoxide Generation which Results in Abnormal Endothelium-Dependent Relaxation.
Zidovudine (AZT) refusal and non-compliance.
Zidovudine (AZT) resistance is suppressed by mutations conferring HIV-1 resistance to foscarnet (PFA).
Zidovudine (AZT) resistance is temporally associated with clinical failure in patients on AZT therapy.
Zidovudine (AZT) toxicity in a cohort of asymptomatic HIV-infected Mexican patients.